TriangleDISEASE & TREATMENT SETTING
Small Cell Lung Cancer
Source-derived catalogue. This is not a treatment recommendation or a personalised trial match.
Exact scope
Small Cell Lung Cancer
- Source population
- Not part of this definition
- Disease extent
- Not part of this definition
- Treatment line
- Not part of this definition
- Stage
- Not part of this definition
- Resectability
- Not part of this definition
Biomarkers, prior therapy and derivation
- molecular
- prior therapy
- derivation status
- source-attested
- derivation note
- Derived from NCI topic(s): Small Cell Lung Cancer. Strongest NCIt resolution: exact. Entity-level scope; stage, biomarker and treatment line are not yet part of this definition.
- source wording
- Source null
20 more-specific settings
Zepzelca: metastatic Small Cell Lung Cancer after prior therapy →Imdelltra: Small Cell Lung Cancer after prior therapy →ETOPOPHOS: Small Cell Lung Cancer (first-line) →HYCAMTIN: Small Cell Lung Cancer (first-line) after prior therapy →Avopef: Small Cell Lung Cancer (first-line) →IMFINZI: Small Cell Lung Cancer after prior therapy →Avopef: refractory Small Cell Lung Cancer →HYCAMTIN: recurrent Small Cell Lung Cancer (first-line) →VePesid: Small Cell Lung Cancer (first-line) →Topotecan: Small Cell Lung Cancer (first-line) after prior therapy →ZEPZELCA: Small Cell Lung Cancer (first-line) after prior therapy →IMFINZI: Small Cell Lung Cancer (first-line) →ETOPOSIDE: Small Cell Lung Cancer (first-line) →IMDELLTRA: Small Cell Lung Cancer after prior therapy →HYCAMTIN: recurrent Small Cell Lung Cancer →TECENTRIQ: Small Cell Lung Cancer (first-line) →ZEPZELCA: metastatic Small Cell Lung Cancer after prior therapy →HYCAMTIN: Small Cell Lung Cancer (first-line) after prior therapy →Tecentriq Hybreza: Small Cell Lung Cancer (first-line) →recurrent Small Cell Lung Cancer →
Study evidence for this setting
Phase 1b/2 Study of Carfilzomib in Relapsed Solid Tumors, Multiple Myeloma, or Lymphoma
Early Palliative Care in Advanced Lung and Gastrointestinal Malignancies
Study of Sacituzumab Govitecan-hziy (IMMU-132) in Adults With Epithelial Cancer
Doxepin Hydrochloride in Treating Esophageal Pain in Patients With Thoracic Cancer Receiving Radiation Therapy to the Thorax With or Without Chemotherapy
Early Palliative Care With Standard Care or Standard Care Alone in Improving Quality of Life of Patients With Incurable Lung or Non-colorectal Gastrointestinal Cancer and Their Fam
Trial of Topotecan With VX-970 (M6620), an ATR Kinase Inhibitor, in Small Cell Cancers and Extrapulmonary Small Cell Cancers
Trilaciclib (G1T28), a CDK 4/6 Inhibitor, in Combination With Etoposide and Carboplatin in Extensive Stage Small Cell Lung Cancer (SCLC)
Trilaciclib (G1T28) in Patients With Previously Treated Extensive Stage SCLC Receiving Topotecan Chemotherapy
A Study of Carboplatin Plus Etoposide With or Without Atezolizumab in Participants With Untreated Extensive-Stage (ES) Small Cell Lung Cancer (SCLC)
Carboplatin, Etoposide, and Atezolizumab With or Without Trilaciclib (G1T28), a CDK4/6 Inhibitor, in Extensive-Stage SCLC
A Study of Pembrolizumab (MK-3475) in Combination With Etoposide/Platinum (Cisplatin or Carboplatin) for Participants With Extensive Stage Small Cell Lung Cancer (MK-3475-604/KEYNO
Health Care Coach Support in Reducing Acute Care Use and Cost in Patients With Cancer
Study of the Safety, Pharmacokinetics and Efficacy of Tinostamustine in Patients With Advanced Solid Tumors.
Study of Durvalumab + Tremelimumab, Durvalumab, and Placebo in Limited Stage Small-Cell Lung Cancer in Patients Who Have Not Progressed Following Concurrent Chemoradiation Therapy
[68Ga]-NeoBOMB1 Imaging in Patients With Malignancies Known to Overexpress Gastrin Releasing Peptide Receptor (GRPR)
Galinpepimut-S in Combination With Pembrolizumab in Patients With Selected Advanced Cancers
Study of Nanrilkefusp Alfa Alone and With Pembrolizumab in Adult Patients With Advanced/Metastatic Solid Tumors
Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV
Surufatinib in Combination With Tislelizumab in Subjects With Advanced Solid Tumors
A Phase III, Open-Label Study of Maintenance Lurbinectedin in Combination With Atezolizumab Compared With Atezolizumab in Participants With Extensive-Stage Small-Cell Lung Cancer
Indication-specific source history
2020-06-15 · Zepzelca (lurbinectedin) · accelerated approval
- release id
- clinical-indications-draft-1
- disease state id
- ds-small-cell-lung-cancer
- event id
- fda-9298d5fd19225e5c
- event date
- 2020-06-15
- event kind
- accelerated-approval
- drug or regimen
- Zepzelca (lurbinectedin)
- source indication text
- Treatment of adult patients with metastatic small cell lung cancer (SCLC) with disease progression on or after prior platinum-based chemotherapy.
- match phrase
- small cell lung cancer
- match status
- candidate
- status category
- ongoing
- has date discrepancy
- 0
- source collection
- fda-status-row
- source key
- fda-aa-0ad64c5b6a6d3d39fe10
- source url
- https://www.fda.gov/drugs/resources-information-approved-drugs/ongoing-cancer-accelerated-approvals
- curation status
- draft
- reviewed by
- Source null
- reviewed at
- Source null
- created at
- 2026-09-10T00:00:00Z
2024-05-16 · Imdelltra (tarlatamab-dlle) · accelerated approval
- release id
- clinical-indications-draft-1
- disease state id
- ds-small-cell-lung-cancer
- event id
- fda-b2a35965afd02ba8
- event date
- 2024-05-16
- event kind
- accelerated-approval
- drug or regimen
- Imdelltra (tarlatamab-dlle)
- source indication text
- Adult patients with extensive stage small cell lung cancer (ES-SCLC) with disease progression on or after platinum-based chemotherapy
- match phrase
- small cell lung cancer
- match status
- candidate
- status category
- verified_clinical_benefit
- has date discrepancy
- 0
- source collection
- fda-status-row
- source key
- fda-aa-2ddd2b249830a3d5e47e
- curation status
- draft
- reviewed by
- Source null
- reviewed at
- Source null
- created at
- 2026-09-10T00:00:00Z
2025-10-02 · lurbinectedin in combination with atezolizumab or atezolizumab and hyaluronidase-tqjs · approval notification
- release id
- clinical-indications-draft-1
- disease state id
- ds-small-cell-lung-cancer
- event id
- notice-172f47aaad22790b
- event date
- 2025-10-02
- event kind
- approval-notification
- drug or regimen
- lurbinectedin in combination with atezolizumab or atezolizumab and hyaluronidase-tqjs
- source indication text
- FDA approved lurbinectedin in combination with atezolizumab or atezolizumab and hyaluronidase-tqjs for the maintenance treatment of adult patients with extensive-stage small cell lung cancer whose disease has not progressed after first-line induction therapy with atezolizumab or atezolizumab and hyaluronidase-tqjs, carboplatin, and etoposide.
- match phrase
- small cell lung cancer
- match status
- candidate
- status category
- Source null
- has date discrepancy
- 0
- source collection
- fda-approval-notice
- source key
- fda-2552276b0d3a31f8
- curation status
- draft
- reviewed by
- Source null
- reviewed at
- Source null
- created at
- 2026-09-10T00:00:00Z
2025-11-19 · Imdelltra (tarlatamab-dlle) · traditional approval
- release id
- clinical-indications-draft-1
- disease state id
- ds-small-cell-lung-cancer
- event id
- fda-34bbe73207e89dbb
- event date
- 2025-11-19
- event kind
- traditional-approval
- drug or regimen
- Imdelltra (tarlatamab-dlle)
- source indication text
- Adult patients with extensive stage small cell lung cancer (ES-SCLC) with disease progression on or after platinum-based chemotherapy
- match phrase
- small cell lung cancer
- match status
- candidate
- status category
- verified_clinical_benefit
- has date discrepancy
- 0
- source collection
- fda-status-row
- source key
- fda-aa-2ddd2b249830a3d5e47e
- curation status
- draft
- reviewed by
- Source null
- reviewed at
- Source null
- created at
- 2026-09-10T00:00:00Z
2025-11-19 · tarlatamab-dlle · approval notification
- release id
- clinical-indications-draft-1
- disease state id
- ds-small-cell-lung-cancer
- event id
- notice-ad988eb3e03317d6
- event date
- 2025-11-19
- event kind
- approval-notification
- drug or regimen
- tarlatamab-dlle
- source indication text
- FDA approved tarlatamab-dlle for adults with extensive stage small cell lung cancer with disease progression on or after platinum-based chemotherapy. Tarlatamab-dlle received accelerated approval for this indication in 2024.
- match phrase
- small cell lung cancer
- match status
- candidate
- status category
- traditional
- has date discrepancy
- 0
- source collection
- fda-approval-notice
- source key
- fda-a0a0b26c2d3a3702
- curation status
- draft
- reviewed by
- Source null
- reviewed at
- Source null
- created at
- 2026-09-10T00:00:00Z
Source relationships and population-mapping limitations
- bindings
- release id
- clinical-indications-draft-1
- disease state id
- ds-small-cell-lung-cancer
- binding id
- ncit-C4917
- source collection
- ncit-concept
- source key
- C4917
- source excerpt
- Source null
- match status
- exact
- match note
- Source null
- recorded at
- 2026-09-10T00:00:00Z
- mappings
Download this complete draft source relationship record →
Preserved source evidence · Not medical advice